SCHEMBL1670870

SCHEMBL1670870

CS(=O)(=O)N1CCC(c2cc(F)c(OC3CN(Cc4cccc5ccccc45)C3)c(F)c2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
OPRM1 P35372 2/20 0.42
OPRK1 P41145 2/20 0.42
OPRL1 P41146 1/20 0.42
ACHE P22303 1/20 0.41
RORC P51449 1/20 0.39
TSHR P16473 1/20 0.39
ABL1 P00519 1/20 0.37
SRC P12931 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
EPHX2 P34913 1/20 0.36
PDE2A O00408 1/20 0.35
DPP4 P27487 1/20 0.35
DPP8 Q6V1X1 1/20 0.35
DPP9 Q86TI2 1/20 0.35
DPP7 Q9UHL4 1/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12198368 0.85 TSHR (0.44) MEN1KMT2AOPRM1OPRK1OPRL1
SCHEMBL1670849 0.84 CCR3 (0.46) MEN1KMT2AACHERORC
SCHEMBL1668410 0.78 KDM4E (0.49) MEN1KMT2ARORCTSHREPHX2
SCHEMBL1669002 0.76 HTT (0.41) MEN1KMT2ARORCDPP4DPP8
SCHEMBL1668511 0.75 GPR119 (0.45) MEN1KMT2ARORCDPP4DPP8
SCHEMBL1668540 0.74 IDO1 (0.39) MEN1KMT2ARORCTSHREPHX2
SCHEMBL1669106 0.74 CNR2 (0.35) KMT2AOPRM1OPRL1RORC
SCHEMBL1668975 0.74 GPR119 (0.44) KMT2ANPSR1ALDH1A1
SCHEMBL1669062 0.74 SCN8A (0.40) KMT2ARORC
SCHEMBL1668891 0.74 GPR119 (0.48) KMT2ARORCALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575168-B2 Compounds and compositions as modulators of GPR119 activity IRM LLC (BM) 2013-11-05 US claimed
EP-2486033-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2012-08-15 EP claimed
US-20110245220-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-10-06 US claimed
WO-2011044001-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-04-14 WO claimed
US-8575168-B2 Compounds and compositions as modulators of GPR119 activity IRM LLC (BM) 2013-11-05 US disclosed
US-8575168-B2 Compounds and compositions as modulators of GPR119 activity IRM LLC (BM) 2013-11-05 US disclosed
EP-2486033-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2012-08-15 EP disclosed
US-20110245220-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-10-06 US disclosed
WO-2011044001-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245220-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY GPR119, GPR65, GPR39 MEN1 3081/4885KMT2A 3355/4885OPRM1 309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.